Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib in COVID-19 and influenza pneumonia
NCT06202521Phase 2Terminated
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of silmitasertib in community acquired pneumonia (CAP) (4 arms), sponsored by Senhwa Biosciences, Inc. Primary endpoint: Percentage of Subjects Requiring Hospitalization, Including Emergency Room Visits, or Resulting in Death Due to Progression of CAP Related to SARS-CoV-2 or Influenza at 29 days. Started Mar 2024; status: terminated.
02
Drugs
silmitasertib
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT06202521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202521.